Nama's AI scorecard currently rates 10x Genomics Hold (5.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is TXG's P/E ratio?

10x Genomics trades at a trailing price-to-earnings ratio of 296.4.

When does TXG report earnings?

10x Genomics's next scheduled report is on Feb 11, 2027. Analysts expect EPS of -$0.04.

What is the TXG price target?

The median analyst price target from 14 analysts is $75.00, with a range of $50.00 – $110.00.

Is TXG Shariah compliant?

Nama's AAOIFI-style screen reads 10x Genomics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

10x Genomics (TXG)

Healthcare · Health Information Services · NASDAQ

10x Genomics (TXG) is a Healthcare company in the Health Information Services industry. It has a market capitalization of $7.72B, a trailing price-to-earnings ratio of 296.4 and a free-cash-flow yield of 1.8%. Over the most recent reported fiscal year, revenue grew 5.2%. Nama's AI scorecard rates it Hold, 5.0 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 5.0/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +485.4% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-67.0%

How far the last close sits under the highest price of the past five years.

Market cap	$7.72B
Trailing P/E	296.4
Price / book	9.3
Price / sales	12.5
FCF yield	1.8%
Dividend yield	—
Gross margin	70.0%
Operating margin	-14.9%
Net margin	-12.2%
Revenue growth (YoY)	+5.2%
Revenue growth (3-yr annual)	+7.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Health Information Services

TXG earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate -$0.04). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.03	-$0.02	+250.0%	—
Q2 2026	Aug 6, 2026	$0.03	-$0.02	+250.0%	$151.04M
Q1 2026	May 7, 2026	$0.07	-$0.06	+216.7%	$150.84M
Q4 2025	Feb 12, 2026	$0.07	-$0.04	+275.0%	$166.03M

TXG analyst price target

Median target $75.00 from 14 analysts, ranging $50.00 – $110.00.

Health Information Services peers

Ticker	Company	Market cap	P/E
VEEV	Veeva Systems	$49.18B	35.0
TEM	Tempus AI	$13.87B	—
BTSG	BrightSpring Health Services	$13.36B	39.3
HNGE	Hinge Health	$9.34B	51.7
HQY	HealthEquity	$8.57B	23.3
DOCS	Doximity	$5.79B	23.7
WAY	Waystar	$5.45B	17.2
HTFL	Heartflow	$4.56B	—

Explore live TXG data on Nama Insights →

TXG FAQ

Is TXG a buy?: Nama's AI scorecard currently rates 10x Genomics Hold (5.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is TXG's P/E ratio?: 10x Genomics trades at a trailing price-to-earnings ratio of 296.4.
When does TXG report earnings?: 10x Genomics's next scheduled report is on Feb 11, 2027. Analysts expect EPS of -$0.04.
What is the TXG price target?: The median analyst price target from 14 analysts is $75.00, with a range of $50.00 – $110.00.
Is TXG Shariah compliant?: Nama's AAOIFI-style screen reads 10x Genomics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.